NCT03435289Unknown1 期
A Phase I Study of CPI-613 in Combination With Gemcitabine and Nab-paclitaxel (Abraxane) for Patients With Locally Advanced or Metastatic Pancreatic Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 24
- 试验地点
- 2
- 主要终点
- The maximally tolerated dose of CPI 613 combined with Gemcitabine and nab-paclitaxel
研究概览
简要总结
This is a single arm, open-label study of CPI-613 in combination with gemcitabine and nab-paclitaxel for patients with locally advanced or metastatic pancreatic cancer never treated with systemic chemotherapy.
详细描述
The primary specific aim of the study is to establish the maximum tolerated dose (MTD) of CPI-613 when given in combination with gemcitabine/nab-paclitaxel for patients with locally advanced or metastatic pancreatic cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically documented and measurable stage III or IV pancreatic adenocarcinoma.
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- •First line treatment for patients diagnosed with metastatic disease
- •First line treatment for patients with locally advanced pancreatic cancer who have not been treated with systemic therapies. Prior treatment with chemoradiation is allowed if 4 or more weeks have passed from completion of chemo-radiotherapy.
- •Expected survival > 3 months.
- •Women of child-bearing potential must use accepted contraceptive methods (abstinence, intrauterine device, oral contraceptive, or double barrier device) during the study, and must have a negative serum or urine pregnancy test within 1 week prior to treatment initiation.
- •Fertile men must practice effective contraceptive methods during the study, unless documentation of infertility exists.
- •Laboratory values ≤2 weeks must be:
- •A. Adequate hematologic (platelet count ≥ 100,000 cells/mm^3 or ≥ 100 bil/L; absolute neutrophil count [ANC] ≥ 1500 cells/mm3 or ≥1.5 bil/L; and hemoglobin ≥ 9 g/dL or ≥ 90 g/L).
- •B. Adequate hepatic function (aspartate aminotransferase [AST/SGOT] ≤ 3x upper normal limit [UNL], alanine aminotransferase [ALT/SGPT] ≤ 3x UNL (≤ 5x UNL if liver metastases present), Total bilirubin ≤ 1.5x ULN C. Adequate renal function (serum creatinine ≤ 2.0 mg/dL or 177 μmol/L). D. Adequate coagulation (International Normalized Ratio or INR must be ≤ 1.5), unless the patient receives anticoagulation treatment in which case the INR should be within the therapeutic level, not higher than 3.5 E. Albumin > 2.5 g/dL
- •No evidence of active infection and no serious infection within the past month.
- •Mentally competent, ability to understand and willingness to sign the informed consent form.
排除标准
- •Unwilling or unable to follow protocol requirements. Endocrine or acinar pancreatic carcinoma
- •Known cerebral metastases, central nervous system (CNS), or epidural tumor
- •Prior treatment with any systemic chemotherapy for metastatic adenocarcinoma of the pancreas or for stage III (locally advanced) adenocarcinoma
- •Presence of clinically significant abdominal ascites
- •Patients receiving any other standard or investigational treatment for their cancer, or any other investigational agent for any indication within the past 2 weeks prior to initiation of CPI-613 treatment.
- •Serious medical illness that would potentially increase patients' risk for toxicity.
- •Any active uncontrolled bleeding, and any patients with a bleeding diathesis (e.g., active peptic ulcer disease).
- •Pregnant women, or women of child-bearing potential not using reliable means of contraception (because the teratogenic potential of CPI-613 is unknown).
- •Lactating females.
- •Fertile men unwilling to practice contraceptive methods during the study period.
- •Life expectancy less than 3 months.
- •Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of patients.
- •Unwilling or unable to follow protocol requirements.
- •Active heart disease including but not limited to symptomatic congestive heart failure (NYHA class 3 or 4), symptomatic coronary artery disease, symptomatic angina pectoris, or symptomatic myocardial infarction.
- •Patients with a history of myocardial infarction that is <3 months prior to registration.
- •Evidence of active infection, or serious infection within the past month.
- •Patients with known HIV infection.
- •Patients who have received cancer immunotherapy of any type within the past 2 weeks prior to initiation of CPI-613 treatment. Steroid use for contrast induced allergy or other supportive care indication is allowed
- •Requirement for immediate palliative treatment of any kind including surgery.
- •Any other malignancy within last 3 years
- •History of interstitial lung disease, idiopathic pulmonary fibrosis or pulmonary hypersensitivity pneumonitis
- •Peripheral neuropathy grades 2 or higher
研究组 & 干预措施
CPI-613, Gemcitabine and Nab-paclitaxel
Other
CPI-613 in Combination With Gemcitabine 1000mg/m2 iv and Nab-paclitaxel 125mg/m2 iv
干预措施: CPI 613 in Combination With Gemcitabine and Nab-paclitaxel (Drug)
结局指标
主要结局
The maximally tolerated dose of CPI 613 combined with Gemcitabine and nab-paclitaxel
时间窗: Evaluation at monthly intervals through study completion from the date of study entry until the date of progression, up to 1 year
次要结局
- The number of participants with treatment related adverse events as assessed by CTCAE v 4.0(Evaluation at 2 week intervals through study completion from the date of study entry until the date of progression, up to 1 year)
- The number of participants with complete or partial response(Evaluation at 2 month intervals through study completion from the date of study entry until the date of progression, up to 1 year)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin LymphomaAdult Lymphocyte Depletion Hodgkin LymphomaAdult Lymphocyte Predominant Hodgkin LymphomaAdult Mixed Cellularity Hodgkin LymphomaAdult Nasal Type Extranodal NK/T-cell LymphomaAdult Nodular Sclerosis Hodgkin LymphomaAngioimmunoblastic T-cell LymphomaHepatosplenic T-cell LymphomaAnaplastic Large Cell LymphomaNoncutaneous Extranodal LymphomaPeripheral T-cell LymphomaRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Hodgkin LymphomaRecurrent Adult T-cell Leukemia/LymphomaRecurrent Cutaneous T-cell Non-Hodgkin LymphomaRecurrent Mycosis Fungoides/Sezary SyndromeT-cell Adult Acute Lymphoblastic LeukemiaT-cell Large Granular Lymphocyte LeukemiaNCT02168140Wake Forest University Health Sciences16
已完成
1 期
CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic CancerAcinar Cell Adenocarcinoma of the PancreasDuct Cell Adenocarcinoma of the PancreasRecurrent Pancreatic CancerStage IV Pancreatic CancerNCT01835041Wake Forest University Health Sciences21
已完成
1 期
Phase I study of nab-paclitaxel and gemcitabine CRT for BR and UR-LA PDACPancreatic cancerJPRN-jRCTs041180147Kishiwada Masashi15
进行中（未招募）
1 期
A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.Pancreas CancerNCT05497778M.D. Anderson Cancer Center19
终止
1 期
Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)Biliary Tract CancerNCT04203160University of Michigan Rogel Cancer Center75